Nat. Rev. Cardiol. doi: /nrcardio

Slides:

Advertisements

Similar presentations

The TRial Of Preventing HYpertension (TROPHY) TROPHY.

Advertisements

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Muscle structure

Nat. Rev. Cardiol. doi: /nrcardio

Systolic Blood Pressure Intervention Trial (SPRINT)

Figure 5 BMI and cardiorespiratory fitness levels

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 4 BMI and mortality in patients with heart failure

Nat. Rev. Cardiol. doi: /nrcardio

Figure 5 Two approaches to therapeutic genome editing

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Experimental design

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Global rates of sodium, fruit, and vegetable intake

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

Figure 2 Size categorization of airborne pollutants

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Three-year survival rates on the basis of body composition

Figure 5 Risk factor control in the intensive treatment group

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 8 4D magnetic resonance imaging patterns

Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.

Figure 6 Pharmacodynamic profile of switching between clopidogrel and ticagrelor therapy: results from the RESPOND study Figure 6| Pharmacodynamic profile.

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Health-care system today

Figure 1 Cardiovascular risk and disease across the life-course

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Decision tree integrating the assessment,

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Global cost of HF per capita in 2012

Figure 2 A patient with aortic stenosis and mitral regurgitation

Figure 5 Examples of biomarker-guided trials

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Milestones in coronary angioplasty

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Challenges for big data applications in cardiovascular care

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Effects of cardiovascular medication on the fetus

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 6 The neurogenic components of angina

Figure 3 Enrichment strategies for clinical trials

Nat. Rev. Cardiol. doi: /nrcardio

Figure 4 Electrocardiogram patterns associated with Brugada syndrome

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Impaired mitochondrial capacity and function in heart failure

Figure 5 Schematic overview of a clinical decision-support

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 5 Algorithm for the management of hypertension

Presentation transcript:

Nat. Rev. Cardiol. doi:10.1038/nrcardio.2017.74 Figure 1 Potential influence of the SPRINT trial in blood-pressure goals in daily clinical practice Figure 1 | Potential influence of the SPRINT trial in blood-pressure goals in daily clinical practice. Potential decisions in clinical practice according to whether the patient with hypertension meets the inclusion criteria for the SPRINT trial (blue). If patients do not meet these criteria, clinicians should probably follow blood-pressure targets recommended in current guidelines (red). The percentage of patients that meet the inclusion criteria (and are amenable to be 'sprinted') is about 20–30% of all patients with hypertension, compared with 70–80% of patients with hypertension who do not meet the SPRINT criteria (estimates are based on Refs 31,32). For strict applicability of blood-pressure targets, blood pressure should be measured in an unattended clinical setting such as with the automated office blood-pressure (AOBP) measurement. Ruiz-Hurtado, G. et al. (2017) Has the SPRINT trial introduced a new blood-pressure goal in hypertension? Nat. Rev. Cardiol. doi:10.1038/nrcardio.2017.74